DRIVEN BY POSSIBILITY MARCH 2025 LEGAL DISCLAIMERS 2 The information in this presentation is as of March 21, 2025, unless otherwise noted. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expe ...

Business Update DECEMBER 4, 2023 Safe Harbor and Non-GAAP Disclosures Forward-Looking Statements Certain statements in this document regarding anticipated financial, business, legal or other outcomes including business and market conditions, outlook and other similar statements relating to Regency's future events, developments, or financial or operational performance or results such as our 2023 Guidance, are "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities L ...

Financial Performance & Growth - Protolabs achieved $504 million in revenue in 2023[6] - The company's Non-GAAP gross margin was 45% in 2023[6] - Adjusted EBITDA reached $83 million in 2023[6] - Protolabs Network revenue experienced a 69% year-over-year growth in constant currencies in 2023[60] - The company's revenue increased by 5% year-over-year, excluding Japan, in 2023[56] Customer Base & Manufacturing - Protolabs has served over 53,000 customer contacts[6,36] - The company has manufactured over 450 million parts to date[6] - Over 85% of Fortune 500 companies in target industries are served by Protolabs[36] - More than 90% of revenue comes from returning customers[44] Market & Outlook - Protolabs operates in a $100 billion+ market[8,14,18] - The company anticipates Q1 2024 revenue between $120 million and $128 million, representing a growth range of -5% to 2% year-over-year[73] - Non-GAAP EPS for Q1 2024 is projected to be between $0.26 and $0.34, indicating a year-over-year growth range of -12% to 15%[73]

Company Overview - PennantPark is an independent private credit platform investing since 2007, focused on the core middle market[2] - The platform has deployed over $21 billion of capital across 745 investments[2] - As of September 30, 2024, PennantPark has $83 billion of AUM[2] Investment Strategy & Portfolio - PennantPark targets profitable, growing companies with $10 million to $50 million of EBITDA[7] - The company actively covers 770+ middle market private equity sponsors in the U S [9] - PennantPark's first lien loans have a cumulative default rate of 3 89% based on capital invested, with a recovery rate of 73 5% (principal only) and 91 6% (all proceeds)[14] - Since 2018, over 75% of PennantPark's deals have been with repeat private equity sponsors[13] Market Positioning - The U S middle market generates $10 trillion of annual revenue, representing 1/3 of the U S economy[23] - Core middle market first lien new issue pricing is SOFR + 5 00% to 6 50%, while second lien is SOFR + 7 50% to 10 00%[20] PFLT Performance & Structure - PFLT's market value of investments is $2 0 billion as of September 30, 2024, primarily in first lien senior secured loans (88%)[29] - PFLT reported $18 0 million of Net Investment Income during the fiscal fourth quarter[36] - PFLT's core NII per share was $0 32 during the quarter, with an annualized dividend yield on NAV of 10 9%[36]

PennantPark Overview - PennantPark is an independent private credit platform investing since 2007, with over $26 billion of capital deployed[3] and $10 billion of AUM as of March 31, 2025[3] - The firm targets profitable, growing, and cash-flowing companies with $10 million to $50 million of EBITDA[9] - PennantPark actively covers 770+ middle market PE sponsors in the U S[11], closing deals with 240+ PE sponsors[11] Investment Strategy & Performance - PennantPark focuses on capital preservation, resulting in low annualized loss rates of 0 08% on first lien loans[17, 18] - The cumulative default rate on PennantPark's first lien loans is 3 34% based on capital invested[18] with a recovery rate of 72 8% on principal proceeds only and 91 8% on all proceeds[18] - PFLT's portfolio consists of 159 direct investments with a market value of $2 3 billion as of March 31, 2025[35] PFLT Financial Highlights - PFLT reported $25 0 million of Net Investment Income (NII) during the fiscal second quarter, with $0 28 of core NII per share[36] - PFLT's total assets were $2 472 billion as of March 2025, with a Net Asset Value of $1 067 billion[40] - PFLT has a historically consistent monthly dividend of $0 1025, with an annualized dividend yield on NAV of 11 1% during the quarter[36]

PennantPark Overview - PennantPark is an independent private credit platform investing since 2007, with over $26 billion of capital deployed[3] and $10 billion of AUM as of March 31, 2025[3] - The firm targets profitable, growing, and cash-flowing companies with $10 million to $50 million of EBITDA[9] - PennantPark actively covers 770+ middle market PE sponsors in the U S[11], closing deals with 240+ PE sponsors[11] Investment Strategy & Performance - PennantPark focuses on capital preservation, resulting in low annualized loss rates of 0 08% on first lien loans[17, 18] - The cumulative default rate on PennantPark's first lien loans is 3 34% based on capital invested[18] with a recovery rate of 72 8% on principal proceeds only and 91 8% on all proceeds[18] - PFLT's portfolio consists of 159 direct investments with a market value of $2 3 billion as of March 31, 2025[35] PFLT Financial Highlights - PFLT reported $25 0 million of Net Investment Income (NII) during the fiscal second quarter, with $0 28 of core NII per share[36] - PFLT's total assets were $2 472 billion as of March 2025, with a Net Asset Value of $1 067 billion[40] - PFLT has a historically consistent monthly dividend of $0 1025, with an annualized dividend yield on NAV of 11 1% during the quarter[36]

Financial Performance & Outlook - SkyWater reported Q1 2025 revenue of $613 million, exceeding the midpoint of their guidance[131] - The company anticipates approximately 5% revenue growth for the combined ATS and Wafer Services business in fiscal year 2025, with a potential variance of ± 2%[40] - SkyWater expects Tools revenue to be around $30 million, primarily concentrated in the second half of the year and related to the Florida operations[140] - For Q2 2025, SkyWater projects total revenues in the range of $55 million to $60 million, with ATS revenues between $49 million and $53 million, Wafer Services revenues between $5 million and $6 million, and Tools revenue just under $1 million[40] Strategic Initiatives - SkyWater announced the acquisition of Infineon's Austin Fab 25 for $110 million, which is expected to add approximately $300 million in annual revenue[104] - The company secured $120 million in DOD program funding for a 300mm wafer fan-out initiative, with initial ATS revenues anticipated in the second half of fiscal year 2025[96] - SkyWater's customer-funded CapEx model has resulted in expected total funding of approximately $322 million from 2020 to 2026[97] Market & Technology Focus - SkyWater is targeting a $9 billion thermal imaging market opportunity by 2027, leveraging its ThermaView platform[25] - The company is actively involved in enabling the quantum revolution, providing custom technology development and manufacturing for superconducting qubits and photonics qubits[36, 38, 143] - SkyWater is expanding its capabilities in advanced packaging, including fan-out wafer-level packaging and hybrid wafer bonding, to support AI processors and heterogeneous systems[95]

Company Overview - Intrusion Inc offers cybersecurity solutions, including Intrusion Shield, leveraging proprietary threat intelligence and AI-based analysis[10, 36] - The company's technology includes a database with historical data on over 85 billion IPs[10] - Intrusion's solutions protect against inbound and outbound threats, identify threats in real-time, and optionally block malicious connections[9] Business Highlights - In 2025, Intrusion took actions to strengthen its balance sheet, resulting in $145 million in proceeds and the elimination of $101 million notional value of Series A Preferred Stock[21] - In 2024, Intrusion signed 20 new Intrusion Shield logos[24] - Intrusion signed a $20 million contract with the U S Department of Defense to support cybersecurity efforts[24] Market and Product - The cybersecurity market is experiencing growing demand, with economic impact of cybercrime reaching $105 trillion[26] - Intrusion Shield Command Hub harnesses AI for smarter cybersecurity[24] - Intrusion offers Shield OnPremise, Shield Cloud, and Shield Endpoint to protect various network environments[47] Financials - As of March 31, 2025, Intrusion had $107 million in cash and cash equivalents and $179 million in net equity[55] - Total common stock outstanding as of March 31, 2025, was 19,895,095 shares, with affiliates holding 40%[58] - Intrusion's revenue for the first quarter of 2025 was $18 million[59]

43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 CRISPR THERAPEUTICS – CONFIDENTIAL © 2025 CRISPR Therapeutics | 11 Forward-Looking Statements This presentation and related materials may contain statements regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by ...

CASGEVY & Hemoglobinopathies - CASGEVY, a CRISPR-Cas9 therapy for severe sickle cell disease and beta thalassemia, is approved in multiple jurisdictions, with >65 authorized treatment centers activated globally and ~90 patients having initiated cell collection as of May 1st, 2025[9, 23] - The addressable market for CASGEVY is approximately 60,000 severe patients in approved territories[19] - A new CMMI model aims to improve access and health outcomes for sickle cell disease, potentially reducing U S expenditures by $3 billion annually[21] CAR T Programs - CTX112, an allogeneic CAR T therapy, demonstrated an overall response rate (ORR) of 67% and a complete response rate (CR) of 50% in a Phase I/II trial (N=12) for relapsed or refractory B-cell malignancies[40] - Updated CTX112 data (N=25) showed cell expansion comparable to autologous CAR T therapies, with dose-dependent increases in AUC and Cmax[43, 46] - In a subset of patients receiving CTX112 post-T cell engager (TCE) therapy, the overall response rate was 100% (6 patients)[48] In Vivo Programs - Initial results from the CTX310 Phase 1 dose escalation trial (N=10) showed promising efficacy, with one patient at the 0 8 mg/kg dose level experiencing an 82% reduction in triglycerides from a baseline of 1073 mg/dL at day 30[62, 66] - Preclinical data for CTX320 in NHPs demonstrated ~70% editing of LPA and ~95% reduction in plasma Lp(a) sustained at 2 years at 2 mg/kg dose[73] - CTX320 has the potential to benefit >60 million U S patients with elevated Lp(a)[81] Financials & Outlook - The company has a strong balance sheet with approximately $1 86 billion[15]